Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 2, 2015, Pages 308-315

  Kashihara, Hideya ^a   Shimada, Mitsuo ^a   Kurita, Nobuhiro ^a   Sato, Hirohiko ^a   Yoshikawa, Kozo ^a   Higashijima, Jun ^a   Chikakiyo, Motoya ^a   Nishi, Masaaki ^a   Takasu, Chie ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bariatric surgery; Gastrointestinal hormone; Incretin; Liraglutide

Indexed keywords

BILE ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIRAGLUTIDE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DUODENAL JEJUNAL BYPASS; FATTY LIVER; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INTESTINE BYPASS; L CELL LINE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT GAIN; ANIMAL; BARIATRIC SURGERY; BLOOD; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; ENTEROENDOCRINE CELL; GENETICS; ILEUM; LONG EVANS RAT; METABOLISM; MOUSE; PROCEDURES; SECRETION (PROCESS); UPREGULATION;

ANIMALS; BARIATRIC SURGERY; BILE ACIDS AND SALTS; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS; ENTEROENDOCRINE CELLS; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; ILEUM; MALE; MICE; RATS, LONG-EVANS; RNA, MESSENGER; UP-REGULATION;

EID: 84921520899     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12690     Document Type: Article

References (35)

1. Pories WJ, Swanson MS, Macdonald KG etal. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 1995; 222: 339-350.
2. Schauer PR, Burguera B, Ikramuddin S etal. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann. Surg. 2003; 238: 467-484.
3. Scopinaro N, Gianetta E, Adami GF etal. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996; 119: 261-268.
4. Rubino F, Forgione A, Cummings DE etal. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann. Surg. 2006; 244: 741-749.
5. Pacheco D, de Luis DA, Romero A etal. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am. J. Surg. 2007; 194: 221-224.
6. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann. Surg. 2004; 239: 1-11.
7. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J. Clin. Endocrinol. Metab. 2004; 89: 2608-2615.
8. Patriti A, Fcchiano E, Sanna A etal. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes. Surg. 2004; 14: 840-848.
9. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
10. Nauck MA, Bartels E, Orskov C etal. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 1993; 76: 912-917.
11. Thomas C, Gioiello A, Noriega L etal. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009; 10: 167-177.
12. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 2005; 329: 386-390.
13. Knudsen LB, Nielsen PF, Huusfeldt PO etal. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000; 43: 1664-1669.
14. Vilsbøll T, Zdravkovic M, Le-Thi T etal. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
15. Madsbad S, Schmitz O, Ranstam J etal. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
16. Nauck MA, Hompesch M, Filipczak R etal. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycemic control and lowers body weight in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2006; 114: 417-423.
17. Garber A, Henry R, Ratner R etal. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
18. Gupta NA, Mells J, Dunham RM etal. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584-1592.
19. Kashihara H, Shimada M, Kurita N etal. Duodenal-jejunal bypass improves insulin resistance by enhanced glucagon-like peptide-1 secretion through increase of bile acids. Hepatogastroenterology 2013 (in press).
20. Sidhu SS, Thompson DG, Warhurst G etal. Fatty acid-induced cholecystokinin secretion and changes in intracellular Ca2+ in two enteroendocrine cell lines, STC-1 and GLUTag. J. Physiol. 2000; 528: 165-176.
21. Brunt EM, Janney CG, Di Bisceglie AM etal. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-2674.
22. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
23. Abu-Hamadah R, Rabiee A, Meneilly GS etal. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 2009; 94: 1843-1852.
24. Salehi M, Aulinger BA, D'Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr. Rev. 2008; 29: 367-379.
25. Patriti A, Facchiano E, Annetti C etal. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes. Surg. 2005; 15: 1258-1264.
26. Suzuki S, Ramos EJ, Goncalves CG etal. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005; 138: 283-290.
27. Rohit Kohli MK, Setchell KDR etal. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity related co-morbidities. Am. J. Physiol. Gastrointest. Liver Physiol. 2010; 299: G652-660.
28. Patti ME, Houten SM, Bianco AC etal. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1671-1677.
29. Sato M, Shibata C, Kikuchi D etal. Effects of biliary and pancreatic juice diversion into the ileum on gastrointestinal motility and gut hormone secretion in conscious dogs. Surgery 2010; 148: 1012-1019.
30. Van Citters GW, Lin HC. Ileal brake: neuropeptidergic control of intestinal transit. Curr. Gastroenterol. Rep. 2006; 8: 367-373.
31. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007; 87: 1409-1439.
32. Watanabe M, Houten SM, Mataki C etal. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489. Epub 2006 Jan 8.
33. Shimabukuro M, Koyama K, Chen G etal. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc. Natl Acad. Sci. U.S.A. 1997; 94: 4637-4641.
34. Mells JE, Fu PP, Sharma S etal. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G225-G235.
35. Kohli R, Setchell KD, Kirby M etal. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology 2013; 154: 2341-2351.